BVS's beat-heavy earnings track record and attractive valuation are balanced against overbought technical conditions and unusually elevated options hedging ahead of its next report.
Thesis pillars
- Elevated Put Call Hedging→Stable
- Earnings Beat Streak→Stable
- Attractive Valuation→Stable
- +1 more pillar — see the Why tab for full reasoning
Bioventus Inc. (BVS) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Devices
Sell if holding. At $12.11, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.3%; Near 52-week high (-1.2% away).
Bioventus is a global medical device company offering pain treatment, surgical solutions, and restorative therapy products for musculoskeletal conditions, organized into U.S. and International segments that generated 88% and 12% of net sales, respectively, in fiscal 2025. Its HA... Read more
Sell if holding. At $12.11, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.3%; Near 52-week high (-1.2% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Bioventus Inc.
About Bioventus Inc.
Bioventus draws 49% of total revenue from its hyaluronic acid viscosupplementation products, up from 46% in 2024 and 43% in 2023, within a portfolio split 88% U.S. and 12% international by net sales. The company markets EXOGEN bone-growth stimulation, neXus-branded surgical instruments, and OSTEOAMP bone graft substitutes, and received FDA 510(k) clearance for its TalisMann and StimTrial peripheral nerve stimulation devices in July 2025.
Bioventus organizes its portfolio into three clinical groups: Pain Treatments (HA injections including Durolane, GELSYN-3 and SUPARTZ FX, plus the XCELL PRP system distributed exclusively in the U.S. under an agreement with Apex Biologix), Surgical Solutions (the neXus ultrasonic platform and OSTEOAMP/SIGNAFUSE bone graft substitutes), and Restorative Therapies (EXOGEN ultrasound bone stimulation). Products reach the market through direct sales teams domestically and a mix of direct, indirect and distributor channels internationally, supported by a market-access team focused on integrated healthcare delivery networks, group purchasing organizations and payers. Competitors named in the filing include Johnson & Johnson, Zimmer Biomet, Stryker, Medtronic, NuVasive and Orthofix. A limited number of third-party manufacturers produce Bioventus's HA products, EXOGEN components and certain surgical products under FDA Quality System Regulation requirements.
Show full overview
Bioventus's reliance on a limited number of FDA-QSR-qualified third-party manufacturers for its HA products, EXOGEN components and PNS devices creates a supply-chain choke point distinct from its product-revenue concentration: the 10-K states that manufacturing is not easily transferable to other sites if a contractor experiences a breakdown, bankruptcy or quality failure, and that finding a replacement manufacturer meeting the company's quality standards could take significant time or fail entirely. Combined with the 49% revenue share carried by HA products, a disruption at even one contract manufacturer could disproportionately affect Bioventus's largest product line.
See also: Healthcare · Medical Devices
From Bioventus Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Bioventus Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga Jul 2, 2026 neutral
Generated 2026-07-08T23:03:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductHA products49%10-K Item 1A: 'Our HA products accounted for 49%, 46% and 43% of our total revenue for the years ended December 31, 2025, 2024 and 2023, respectively.'
- MEDIUMSupplierthird-party manufacturers10-K Item 1A: 'We rely on a limited number of third-party manufacturers to manufacture certain of our products and critical components.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $12.11, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.3%; Near 52-week high (-1.2% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.26. Score 5.9/10, moderate confidence.
Take-profit target: $12.88 (+6.4% upside). Prior stop was $11.26. Stop-loss: $11.26.
Thin upside margin: 6.3%; Near 52-week high (-1.2% away); Leverage penalty (D/E 1.2): -0.5.
Bioventus Inc. trades at a P/E of 28.7 (forward 13.0). TrendMatrix value score: 6.4/10. Verdict: Sell.
9 analysts cover BVS with a consensus score of 4.1/5. Average price target: $15.
What does Bioventus Inc. do?Bioventus is a global medical device company offering pain treatment, surgical solutions, and restorative therapy...
Bioventus is a global medical device company offering pain treatment, surgical solutions, and restorative therapy products for musculoskeletal conditions, organized into U.S. and International segments that generated 88% and 12% of net sales, respectively, in fiscal 2025. Its HA viscosupplementation products (Durolane, GELSYN-3, SUPARTZ FX) accounted for 49% of total revenue in 2025, alongside surgical solutions (neXus, BoneScalpel, OSTEOAMP) and restorative therapies (EXOGEN bone stimulation). Products are sold through direct and indirect sales teams and distributors in the U.S. and internati